Glucose Level and Body Mass Index (BMI) Among Chronic Psychotic Patients Treated with A Typical Antipsychotic (Olanzapine) or Traditional Antipsychotic or Both of Them. In Nasiriya City \ Iraq.
DOI:
https://doi.org/10.61841/va3gaa55Keywords:
Glucose Level, BMI, Olanzapine, Traditional Antipsychotic, Nassirya City, IraqAbstract
Background: Schizophrenic and manic depressive patients treated with olanzapine have a 1.5-2 times higher rate of diabetes mellitus and obesity in comparison with the normal population (1). It was observed that traditional antipsychotics are associated with hyperglycemia in uncontrolled studies (2). This study facilitates a chance to study the side effects of both typical and atypical antipsychotic drugs on glucose during prospective trials (3), with probable explanations related to increased body weight due to atypical antipsychotic blockage of hypothalamic H1 receptors or serotonergic 5-HT receptor antagonism. (4)
Aims of Study: The Study assessed the glucose level and BMI through a period of treatment with olanzapine, a traditional antipsychotic, or both drugs on a study sample. Also, studying the effect of various risk factors like sociodemographic variables, type of treatment (T0T), duration of disease (DOD), and random blood sugar (RBS).
Methods: Seventy patients (20 and 50 females) with chronic psychotic disorder or manic depressive psychoses were out outpatients studied in crosssectional approach. An established evaluation consist patients treated for many years with atypical, traditional antipsychotic, or both drugs, involving RBSglycated hemoglobin HbA1cand BMI for the period March 1 to September 1, 2019. DSM-IV criteria was used for diagnosis of mental disorders
Ethics: Verbal and written consent was taken from patients and their relatives
Result: Most of the patients were diagnosed with chronic psychotic or manic depressive psychoses or other psychiatric disorders treated for one year or more. 70 patients of study sample (20 male, 50 female) (48.6%) were on olanzapine (20%) Were treated with traditional antipsychotics (31.4%) were on both drugs; most of patients were obese (35.7%) weight (37.1%); 14.3study sample were diabetic; 85.7% were with normal HbA1C; other correlated variables to diabetes mellitus were studied in various statistical approaches
Conclusion: Cross sectional study of sample treated with olanzapine, traditional antipsychotics or both to reveal level of HbA1cand other relevant variables
Downloads
References
[1] Guo JJ, keck pE, corey- lisle pket..al.’’ Risk of diabetes mellitus associated with atypical antipsychotic
used among bipolar disorder: are terospective, popnlatio based, case control study. J clinic psychiatry.
2006:67; 1055-61.
[2] Lindenman J,czobor p, volavka et.. al. Change in cholesterol level in patients with schizophrenia treated
with typical or a typical antipsychotic’’. Am. J psychiatry, 160: 290-296:2, February2003.
[3] Burke Jp, William k,Gaskill Sp, Hazuda Hp, Haffner M,SternMP’’Rapidriseintheincidenceoftype2 diabetes
from 1987 to 1996 results from san Antonio Heart study’’. Antonion Heart study. Arch intern med 1999;
159:1450-1456.
[4] StahlSM, MigronL, meyer JM; which come first A typical antipsychotic treatment or cardio metabolic risk?
Acta psychiatric scandanvica 2009; 119(3):171-179.
[5] Fraguas, D, correll. C.V; Merchan –Naranjo, J.,Rapadocastro, M, parellada, M, Moreno, C., et al .‘Efficacy
and safety of second –generation antipsychotic in children and adolescent with psychotic and bipolar
spectrum disorder comprehensive review of prospective head to head and placebo controlled comparision’’.
Eurneuro psychopharmacal.21.621-645 dol10:1007J. euronento 2010. 07-02.
[6] Ginovart . N., and capur 5 (2012). Role of dopaminD(2) receptors for antipsychotic Hand Exp’’.
Pharamacol 2012 27-52. dio: 10. 1007/978-3-642- 25761-2-2.
[7] Kerala. T, surech. PN ‘’Hyperglycemia associated with olanzapine treatment’’. Kerala medical Journal:
October- December 2011.vol: lv issue 4-
[8] Bechara CL, Goldman Levine JD. ‘’Dramatic word sinening worsening of type 2 diabetes mellitus due to
olanzapine after3yearsoftherapy’’.Pharmacotherapy.2001nov;21 (11):1444-7.
[9] American Diabetes Association. ’Diagnosis and classification of Diabetes Mellitus’’. Diabetic care, volume
34,1January 2011. http:// creative common org / licenses/ by- nc and /3.0/fordetials.
[10] Bromel T, Blum wf, Ziegler A, schulz ZE, etal: ‘’serumleptinlevel increase rapidly afterintiation of
clozapine’’molpsychiatry3:76-80(1980).
[11] Wirshing DA, wirshingwc, kayser L, et.. al‘’ Novel antipsychotics: comparision of weight gain liabilities, J
clinic psychiatry 1999 358-363 crossref, Google scholar.
[12] Segal JC,Verschuren WMW, Vanleer EM, Kromhout D: ‘’OVER weight, underweight and
mortality’’.JclineIvest1987;80:1050-1055crossref, medlin.
[13] Bobo WV,Bonaccorso S, Jayathilake k, Mellzer HY, prediction of metabolic effects of olanzapine and
rispend on treatment from baseline body mass index in schizophrenia and bibolar disorder’’. Psychiatry
Research 2011, volume 189, issue 2 page200-207.
[14] White w,ELmore L, Luthin DR, cates ME.’’ Psychotropic induced weight gain: are view management
strategies 2013:53(3):153-60.
[15] Lieberman JA, Stroup TS, McEvocy JP,et al. ‘’EFF activeness of antipsychotic drugs in patients with
chronic schizophrenia’’ N Eng J med 2005; 353:1209-23.
[16] Fuller MA, Shermock KM, Secic M, George AL.’’ comparative study of development of diabetes mellitus in patients taking respoidal and olanzapine. Pharmaco therapy 2003, Aug: 23(8):1037-43.
[17] Weiden PJ, Dixon L, frances A, etal.‘’Neuroleptic and compliance in Schizophrenia. In: Advances in neuropsychiatry and psychopharmacology ‘’ Tamminga c, Schulz SC, (ED). Newyork. Ravan press, 1991- page: 285-95.
[18] Kim DH, maneen MJ, stahi SM. Building abetter antipsychotic receptor target for the treatment of multiple symptoms dimension of schizophrenia. Neurotherapeutic 2009;6:78-85.
[19] ALEXBERNSON. ‘’The newyorkTimes’’OcT 6, 2007. Page: c3 of the newyork Time edition with headline: Lilly Add strong warning label to zyprexa schizophrenia drug.
[20] Teixeira P,J,R, Rocha F,L ‘’metabolic side effectof antipsychotic and moodstabilizer’’. Revista de psiquiatria do Rio Gramdo do sul.2006: vol:28. Issue:2
[21] aing LIN MA, Houming Liu, WANLIXIN. ‘’Priordiagnosisofdiabetesmellitus’’. Biomedical Report :2016 June; 4(6): 737-740
[22] Debra L,F, Mackinnon D, Watts G,F, DSC, etal. Effect of age, family history of diabetes, and antipsychotic
drugs treatment on risk of diabetes in people with psychoses: a population- based cross-sectional study’’
The LANCET psychiatry.’’2015:vol(2).Issue(2):1092- 1098.
[23] cohen.D,Dekker j,j. peen. J, Gispened c,c Prevelance of diabetes mellitus in chronic schizophrenic in
patients in relation to long- term use of antipsychotic treatment’’ Europian Neuropharmacology.2006-
16(3):187-94.
[24] sursh kumar PN.’’ Hyperglycemia Associated with olanzapinetreatment.’’ Kerala Medica Journal
(2011);4(4):120-121.
[25] Jerrell JM, MC Intyre RS.A.’’Advers events in children and adolescent treated with antipsychotic
medications.’’ Human Psychopharmacology. 2008; volum(23), issue(4).267-354.
[26] Bruce L, Lambert, Franesca E,C. Donaland R,M, Gregoryw.D,KwanH.’’Diabetes Risk associated with use
of olanzapine, Quetiapine and Risperidon in veterans Health Adminstration patients with schizophrenia’’
American J Epidemiolog 2006 vol(164)issu(7):672-681.
[27] Ray WA: ‘’Evaluating medication effects outside clinical trial: new user deign’’ Am J Epidemiol 2003:
158:915-20 Google scholar
[28] vijay K, Schakitala D, Mirza B,Shalu B,et al. comparative evaluation of Olanzapine and Quetiapine on
body mass inder (BMV) in psychotic patients at tertiary care teaching hospital in Nepal’’. International
Journal of medical science and public health; 2016: vol(5). Issue(09): 1911-1915.
[29] Baptista T. ‘’Body weight gain by antipsychotic drugs: mechanism and management’’ Acta psychiatra
Scand : 1999; 100(1):3-16 crossref, medline, Google scholar
[30] Allison DB, Mentore JL, Heo M, chandler LP, infant DM, Weiden PJ. ‘’Antipsychotic- induced weight
gain’’: Acomprehensive research synthesis. Am J psychiatry 1999: 1686-1696. Medline. Google scholar.
[31] SheriR, C: Ronald J, Jane E, Yardley M, etal ‘’physical Activity/ Exercise and Diabetes Apposition
statement of the American associate: 2016; 39(11): 2005-2079.
[32] Nilsen J, Skidbed S, Christophe V,C. ‘’ Antipsychotic Associated with Development of Type 2 Diabetes in
Antipsychotic- naïve Schizophrenic patients’’. Neuropshycho pharmacology 2010:35(9).1997-2004.
[33] Hodgson R, Belgamwar R, Altawarash Y, Mackenzic, “The use of atypical antipsychotic treatment of
schizophrenia in North Standford ‘’. Human psychopharmacology: clinic and experimental 2005 - 20
(2),141-147.
[34] E.A.MGale, K.M Gillespie. ‘’Diabetes and gender’’ Diabetologia: Jan 2001, volume (44), issue1,page. 3-
15.
[35] Matthew J Smith, C. Robert Cloninger,etal..‘Treatment and character as schizophrenia- related
endophenotypes in non. Psychotic siblings’’. Schizophrenia research: 2008. 104 (1-3), page: 198. 2005.
[36] Jocelyne M, Jean-pierre G, Michel G. etal ‘Exploring the risk of diabetes mellitus and dyslipidemia among
ambulatory use of atypical antipsychotic: A population- based of rispenidon and
olanzapine’’. Pharmacoepidemiology and drug safety: 2005. Vol (14) issue(6). Page 427-436
[37] Foster T,D, Kryzhanovsky L,A,etal..‘Impact of olanzapine or rispenidon on insulin sensitivity in
schizophrenic or scherzo affective disorders :2011 volum ( 13)issue 8
[38] Kelly A, C. sheitman B. Harmer R,Bet al‘ anaturalistic comparision of long-term metabolic adverse effects of clozapine verus other antipsychotic Journal of clinical pharmacology: 2014. 34(4)
[39] Feng S, Melkerson k, Metabolic parameters and long- term antipsychotic treatment: A comparision between patients treated with clozapineorolanzapine’’ Neuroendocrino lett 2012. 33(5), 493-408.
[40] Barnes .T, Batti. S,F, Androer. R. etal ‘screening for the metabolic side effects medication finding of 6 year quality improvement program in U.K :2015. volume(5) issue(10).
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
